title: Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
abstract: Pompe disease can be treated effectively, if immune tolerance to enzyme replacement therapy (ERT) with acid α-glucosidase (GAA) is present. An adeno-associated viral (AAV) vector carrying a liver-specific regulatory cassette to drive GAA expression (AAV-LSPhGAA) established immune tolerance in GAA knockout (KO) mice, whereas ubiquitous expression with AAV-CBhGAA provoked immune responses. Therefore, we investigated the hypothesis that immune tolerance induced by hepatic-restricted expression was dominant. AAV-LSPhGAA and AAV-CBhGAA were administered singly or in combination to groups of adult GAA-KO mice, and AAV-LSPhGAA induced immune tolerance even in combination with AAV-CBhGAA. The dual vector approach to GAA expression improved biochemical correction of GAA deficiency and glycogen accumulations at 18 weeks, and improved motor function testing including wire-hang and grip-strength testing. The greatest efficacy was demonstrated by dual vector administration, when both vectors were pseudotyped as AAV8. T cells from mice injected with AAV-LSPhGAA failed to proliferate at all after an immune challenge with GAA and adjuvant, whereas mock-treated GAA-KO mice mounted vigorous T cell proliferation. Unlike AAV-LSPhGAA, AAV-CBhGAA induced selective cytokine and chemokine expression in liver and spleen after the immune challenge. AAV-CBhGAA transduced dendritic cells and expressed high-level GAA, whereas AAV-LSPhGAA failed to express GAA in dendritic cells. The level of transduction in liver was much higher after dual AAV8 vector administration at 18 weeks, in comparison with either vector alone. Dual vector administration failed to provoke antibody formation in response to GAA expression with AAV-CBhGAA; however, hepatic-restricted expression from dual vector expression did not prevent antibody formation after a strong immune challenge with GAA and adjuvant. The relevance of immune tolerance to gene therapy in Pompe disease indicates that hepatic expression might best be combined with nonhepatic expression, achieving the benefits of ubiquitous expression in addition to evading deleterious immune responses.
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Baodong
authors.initials: B
authors.lastname: Sun
authors.forename: Takuya
authors.initials: T
authors.lastname: Osada
authors.forename: Ramona
authors.initials: R
authors.lastname: Rodriguiz
authors.forename: Xiao Yi
authors.initials: XY
authors.lastname: Yang
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Luo
authors.forename: Alex R
authors.initials: AR
authors.lastname: Kemper
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Clay
authors.forename: Dwight D
authors.initials: DD
authors.lastname: Koeberl
mesh_terms: D000818:Animals; D049109:Cell Proliferation; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000201:enzymology / Q000276:immunology; D000229:Dependovirus; D056947:Enzyme Replacement Therapy / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage / Q000378:metabolism; D006009:Glycogen Storage Disease Type II / Q000201:enzymology / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007074:Immunoglobulin G / Q000097:blood; D007275:Injections, Intravenous; D008099:Liver / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D009928:Organ Specificity / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D019076:Transgenes; D000520:alpha-Glucosidases / Q000032:analysis / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D007074:Immunoglobulin G; C509951:GAA protein, human; D000520:alpha-Glucosidases